The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Health plan budget impact of introducing everolimus for treatment of advanced progressive pancreatic neuroendocrine tumors in the United States.
Roman Casciano
Consultant or Advisory Role - Analytica International
Maruit Chulikavit
Consultant or Advisory Role - Analytica International
Michelle Sriprasert
Consultant or Advisory Role - Analytica International
Zhimei Liu
Stock Ownership - Novartis
Xufang Wang
Stock Ownership - Novartis
Louis P Garrison
Consultant or Advisory Role - Universty of Washington